Navigation Links
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ

SAN FRANCISCO, Sept. 18 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 15, 2009, it received a deficiency letter from the NASDAQ Stock Market stating that the Company is not in compliance with the minimum $1.00 per share bid price requirement for continued listing, as set forth in Listing Rule 5550(a)(2), and that the Company's securities are, therefore, subject to delisting from The NASDAQ Capital Market.

The Company has a period of 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price listing requirement. If at any time during this grace period the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Company will receive written notification of its compliance with the minimum bid price listing requirement. In the event the Company does not regain compliance prior to the expiration of the grace period, the Company will receive written notification that its securities are subject to delisting. In such event, the Company may appeal NASDAQ's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which request will stay the delisting of the Company's securities pending the Panel's decision. Additionally, the Company has had a hearing with the Panel regarding its failure to meet capitalization requirements for continued listing and is awaiting a decision from the Panel. There can be no assurance that the Company will regain compliance with the minimum bid price listing or capitalization requirements and maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit:

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the October 31, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our ability to timely recruit and enroll patients in any future
           clinical trials;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of VIA-
           2291 on expected timetables and the outcomes of such clinical
        -- complexities in designing and implementing cardiometabolic clinical
           trials using surrogate endpoints in Phase 1 and Phase 2 clinical
           trials which may differ from the ultimate endpoints required for
           registration of a candidate drug;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of the ACS and CEA studies, upon further review and
           analysis, are revised, interpreted differently by regulatory
           authorities or negated by later stage clinical trials;
        -- our ability to obtain necessary FDA approvals, including to
           initiate future clinical trials of  VIA-2291;
        -- our ability to successfully commercialize VIA-2291;
        -- our ability to identify potential clinical candidates from the
           family of DGAT1 compounds licensed and move them into preclinical
        -- our ability to obtain and protect our intellectual property related
           to our product candidates;
        -- our potential for future growth and the development of our product
           pipeline, including the THR beta agonist candidate and the other
           compounds licensed from Roche;
        -- our ability to obtain strategic opportunities to partner and
           collaborate with large biotechnology or pharmaceutical companies to
           further develop VIA-2291;
        -- our ability to form and maintain collaborative relationships to
           develop and commercialize our product candidates;
        -- general economic and business conditions; and
        -- the other risks described under Item 1A "Risk Factors" in our
           Annual Report on Form 10-K for the fiscal year ended December 31,
           2008, as supplemented by the risks described under Item 1A "Risk
           Factors" in our Quarterly Reports on Form 10-Q for the quarters
           ended March 31, 2009 and June 30, 2009, each on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference
2. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
3. AUDIO from Medialink and Solvay Pharmaceuticals: New High Five Program Addresses Energy Levels of Overweight Men
4. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
5. Merz Pharmaceuticals Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
6. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
7. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
8. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
9. Reportlinker Adds US and European Radiopharmaceuticals Market Report
10. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
11. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... The workstation boundaries for imaging specialists ... Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, debuting ... December 4, 2015. , MED-TAB is expected to change teleradiology because for ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VIEJO, Calif. , Dec. 1, 2015 /PRNewswire/ ... the prevalence of symptoms for pseudobulbar affect (PBA), ... outbursts of laughing and/or crying resulting from certain ... use of antipsychotic medications in nursing home residents, ... Geriatric Psychiatry. The study showed that almost one ...
(Date:12/1/2015)... 1, 2015 ... of the  "2016 Shigella Testing Market: ... Competitive Strategies, Emerging Opportunities--US, Europe (France, ... to their offering. --> ... of the  "2016 Shigella Testing Market: ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
Breaking Medicine Technology: